Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback